[Cardiac failure treatment with berlipril: effects on hemodynamics, neurohumoral status and activity of free radical lipid peroxidation].
OBJECTIVE
To test the ability of ACE inhibitor berlipril to control neurohumoral hyperactivation and reestablish balance between oxidant and antioxidant systems in patients with ischemic heart disease (IHD) associated with heart failure (HF).


METHODS
145 patients (mean age 51.5 +/- 3.94 years) with IHD class II-III associated with circulatory insufficiency NYHA class II-III received berlipril for 6 weeks.


RESULTS
Berlipril treated patients exhibited decreased class of HF, improved left ventricular conductivity, attenuated neurohumoral stimulation, intensity of cell membrane peroxidation, increased plasmic pool of antioxidant enzyme systems.


CONCLUSIONS
6-week berlipril treatment promoted a pronounced improvement of neurohormonal profile of plasm and recovery of free radical lipid peroxidation which resulted in reduction of HF.
Vizir
V A
VA
Berzin
A E
AE
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism*; D004452:Echocardiography; D004656:Enalapril / Q000627:therapeutic use*; D016166:Free Radical Scavengers / Q000378:metabolism*; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D002395:Catecholamines; D016166:Free Radical Scavengers; D004656:Enalapril